C Number:

**Study Gender:** 

**PWG Approval Date** 

R11: Fetal Defect Summary Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine CAS Number: 95737-68-1

R16011D

Female

See web page for date of PWG Approval

## R11: Fetal Defect Summary Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine CAS Number: 95737-68-1

		Treatment Gro	ups (mg/kg/day)	
	0	62.5	125	250
	All Exams	5		
No. Fetuses	214	185	193	136
No. Litters	24	23	22	16
Malformation				
Affected fetuses	13 (6.07)	4 (2.16)	14 (7.25)	11 (8.09)
Affected litters	9 (37.50)	4 (17.39)	11 (50.00)	8 (50.00)
/ariation				
Affected fetuses	72 (33.64)	78 (42.16)	84 (43.52)	55 (40.44)
Affected litters	22 (91.67)	21 (91.30)	22 (100.00)	16 (100.00)
Gross Finding				
Affected fetuses	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.74)
Affected litters	0 (0.00)	0 (0.00)	0 (0.00)	1 (6.25)
	External			
No. Fetuses	214	185	193	136
No. Litters	24	23	22	16
Malformation				
Affected fetuses	1 (0.47)	1 (0.54)	0 (0.00)	0 (0.00)
Affected litters	1 (4.17)	1 (4.35)	0 (0.00)	0 (0.00)
/ariation				
Affected fetuses	1 (0.47)	0 (0.00)	0 (0.00)	0 (0.00)
Affected litters	1 (4.17)	0 (0.00)	0 (0.00)	0 (0.00)

## R11: Fetal Defect Summary Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine CAS Number: 95737-68-1

F0 Female: Main Study Animals						
	Treatment Groups (mg/kg/day)					
	0	62.5	125	250		
	Visceral					
No. Fetuses	214	185	193	136		
No. Litters	24	23	22	16		
Malformation						
Affected fetuses	4 (1.87)	2 (1.08)	4 (2.07)	1 (0.74)		
Affected litters	4 (16.67)	2 (8.70)	4 (18.18)	1 (6.25)		
Variation						
Affected fetuses	7 (3.27)	2 (1.08)	2 (1.04)	2 (1.47)		
Affected litters	5 (20.83)	2 (8.70)	2 (9.09)	2 (12.50)		
	Head - Rab	bit				
No. Fetuses	214	185	191	134		
No. Litters	24	23	22	16		
Malformation						
Affected fetuses	1 (0.47)	0 (0.00)	1 (0.52)	0 (0.00)		
Affected litters	1 (4.17)	0 (0.00)	1 (4.55)	0 (0.00)		

## R11: Fetal Defect Summary Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine CAS Number: 95737-68-1

F0 Female: Main Study Animals						
	Treatment Groups (mg/kg/day)					
	0	62.5	125	250		
	Skeletal					
No. Fetuses	214	185	193	136		
No. Litters	24	23	22	16		
Malformation						
Affected fetuses	8 (3.74) #	2 (1.08)	9 (4.66)	10 (7.35)		
Affected litters	6 (25.00)	2 (8.70)	7 (31.82)	7 (43.75)		
Variation						
Affected fetuses	69 (32.24)	76 (41.08)	83 (43.01)	54 (39.71)		
Affected litters	21 (87.50)	21 (91.30)	22 (100.00)	16 (100.00)		
	Placental					
No. Fetuses	214	185	193	136		
No. Litters	24	23	22	16		
Gross Finding						
Affected fetuses	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.74)		
Affected litters	0 (0.00)	0 (0.00)	0 (0.00)	1 (6.25)		

R11: Fetal Defect Summary Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine CAS Number: 95737-68-1 Date Report Requested: 10/22/2019 Time Report Requested: 12:39:05 Lab: Southern Research

LEGEND

Upper row denotes number of affected fetuses (%) and lower row the number of affected litters (%)

Trend and pairwise significance levels are determined using one-sided tests.

Statistical analysis for fetal data including litter effects were performed by using a Rao-Scott modification to the Cochran-Armitage test where the Doe ID was the random effect for both trend and pairwise analysis.

# Statistically significant at P <= 0.05 (litter based analysis)

## Statistically significant at P <= 0.01 (litter based analysis)

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

Over-maceration during skeletal processing occurred in all groups: control group 47 fetuses[F] (5 litters[L]); limited to phalanges (22F, 3L); with fore/hind limbs (22F, 3L); and included portions of the axial skeleton (7F, 2L); 62.5 mg/kg dose group observed in 2F/2L; limited the phalanges in 1F, and included the fore/hind limbs in 1F; 125 mg/kg dose group (51F, 4L); limited the phalanges (13F, 2L); included fore/hind limbs (21F, 4L) and portions of the axial skeleton (3F, 1L); in the 250 mg/kg dose group (10F, 1L); limited the phalanges in 1F and included the fore/hind limbs in 9F.

\*\* END OF REPORT \*\*